Onvitrelin ucalontide is a synthetic peptide hormone agonist classified as a gonadotropin-releasing hormone (GnRH) analog, primarily investigated for its therapeutic potential in treating prostate cancer… Read more
Onvitrelin ucalontide is a synthetic peptide hormone agonist classified as a gonadotropin-releasing hormone (GnRH) analog, primarily investigated for its therapeutic potential in treating prostate cancer by suppressing testosterone production. By binding to GnRH receptors, it inhibits the release of luteinizing hormone and follicle-stimulating hormone, thereby lowering androgen levels in patients with advanced disease. This category features high-quality reference standards for Onvitrelin ucalontide, including related impurities, metabolites, and stable isotope-labelled compounds. These materials are essential for pharmaceutical laboratories conducting rigorous analytical testing, such as impurity profiling, method validation, and routine quality control. By utilizing these precise analytical standards, researchers can ensure accurate quantification and characterization of the active pharmaceutical ingredient throughout the drug development lifecycle, maintaining the integrity and compliance of their pharmaceutical research and manufacturing processes.